<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397978</url>
  </required_header>
  <id_info>
    <org_study_id>S63789</org_study_id>
    <nct_id>NCT04397978</nct_id>
  </id_info>
  <brief_title>Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases</brief_title>
  <acronym>LAT-MUM</acronym>
  <official_title>Local Ablative Therapy for Patients With Multiple (4-10) Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the quality of life (QOL) and to report on toxicity and outcome parameters after&#xD;
      the (repeated) use of local ablative therapy (LAT) i.e. stereotactic radiotherapy (SRT) for&#xD;
      patients with multiple (4-10) brain metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase IV prospective non-randomized observational trial (registry trial) for patients with a&#xD;
      DS-GPA &gt; 1.5 or an estimated life expectancy of &gt;3 months and an established diagnosis on&#xD;
      dedicated brain MRI of 4-10 BM of any solid primary tumor.&#xD;
&#xD;
      We plan to deliver a local ablative therapy (LAT) i.e. SRT in 1 to 5 fractions on visible BM&#xD;
      and post-surgical cavities if applicable.&#xD;
&#xD;
      Our primary aim is to provide quality of life (QOL) data and our secondary aim is to report&#xD;
      on several toxicity and outcome parameters for this patient cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the EQ-5D-5L questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the QLQ-BN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 3 month after radiotherapy</time_frame>
    <description>Measured by the PRO-CTCAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the QLQ-BN20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From baseline to 1,6,9 and 12 month (+q3month) after radiotherapy</time_frame>
    <description>Measured by the PRO-CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control</measure>
    <time_frame>Time from SRT until local progression or death whichever comes first, up to 3 years after LAT</time_frame>
    <description>Local control of the irradiated metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from SRT until the occurrence of new brain metastases or death whichever comes first, up to 3 years after LAT</time_frame>
    <description>Brain metastasis free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from SRT until death from any cause</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>From baseline to ≤ 90 days after radiotherapy</time_frame>
    <description>Acute toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>From &gt; 90 days after radiotherapy through study completion</time_frame>
    <description>Late toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>Change in toxicity measured from baseline up to 3 years after radiotherapy</time_frame>
    <description>Occurrence of radionecrosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>Local ablative therapy with SRT</description>
    <other_name>SRT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with an established diagnosis on dedicated brain magnetic resonance (MRI) of&#xD;
        4-10 brain metastases (BM) of any solid tumor with an estimated life expectancy of &gt;3&#xD;
        months or a disease specific grade prognostic index (DS-GPA) of ≥ 1.5.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ≥ 18 years of age&#xD;
&#xD;
          2. Minimal 4 and up to a maximum of 10 synchronous BM diagnosed on a high resolution&#xD;
             contrast-enhanced MRI scan (T1 gadolinium) not dated more than 4 weeks prior to&#xD;
             inclusion.&#xD;
&#xD;
          3. Maximal lesion diameter of single gross tumor volume (GTV) of 3 cm&#xD;
&#xD;
          4. Maximal cumulative GTV (+CTV for cavity) of 30cm3&#xD;
&#xD;
          5. Karnofsky performance status ≥ 70&#xD;
&#xD;
          6. DS-GPA or expected overall survival (if no DS-GPA applicable) of ≥ 1.5 or &gt;3 months&#xD;
             respectively.&#xD;
&#xD;
          7. Any solid primary tumour. Lymphoma, germ cell tumor, small cell lung carcinoma and&#xD;
             multiple myeloma are excluded.&#xD;
&#xD;
          8. Ability to provide written informed consent and to participate in the procedure of the&#xD;
             questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BM not amenable to SRT&#xD;
&#xD;
          2. Previous SRT or surgery on the same lesion&#xD;
&#xD;
          3. Co-morbidities considered clinically precluding the safe use of an MRI examination or&#xD;
             SRT&#xD;
&#xD;
          4. Any psychological, sociological or geographical issue potentially hampering compliance&#xD;
             with the study&#xD;
&#xD;
          5. Pregnancy&#xD;
&#xD;
          6. Concurrent use of systemic therapy&#xD;
&#xD;
          7. More than 10 BM on planning-MRI&#xD;
&#xD;
          8. Maximum cumulative GTV (+CTV for cavity) of more than 30cm3 on planning-MRI&#xD;
&#xD;
          9. A brainstem metastasis with a PTV of more than 20 cm3&#xD;
&#xD;
         10. Leptomeningeal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Berkovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maarten Lambrecht, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Oldenburger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>An Nulens</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lien Smets, BA</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Berkovic, MD</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>Patrick.berkovic@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deveny Vanrusselt, BA</last_name>
    <phone>+32-16-34-76-00</phone>
    <email>deveny.vanrusselt@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Berkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maarten Lambrecht, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Oldenburger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Nulens, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lien Smets, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deveny Vanrusselt, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiotherapy</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Multiple (4-10)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

